The Surface Molecular Signature of Leukemic Cells Is Associated with <b><i>NPM1</i></b> Mutations and <b><i>FLT3</i></b>-ITD in Patients with de novo Acute Myeloid Leukemia

Abstract

Certain molecular mutations are associated with signs of cell morphology and differentiation in acute myeloid leukemia (AML). However, only limited data are available for the detailed analysis of such correlations. In this study, AML patients were classified into 4 subsets according to CD34, HLA-DR and CD11c expression levels. Significantly low CD34 antigen expression was observed in nucleophosmin (NPM1)-mutated patients and in those with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). No correlations were observed among NPM1 mutations, FLT3-ITD and monocytic morphology in patients without CD34 expression. Both NPM1 mutations and FLT3-ITD were absent in cluster IIb patients (CD34⁺CD11c^-). The associations among NPM1 mutations, FLT3-ITD and the surface molecular signature of leukemic cells may offer beneficial information about the pathogenesis of AML.

CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection

“…This was further supported by our recent finding that FLT3/ITD mutations are present at the LSC level, which also showed that the oncogenic events of FLT3/ITD occurred at a cell stage possessing the IL-3 receptor α (CD123) [30]. This correlation forms a basis for CD123-targeted therapies in AML with intracellular FLT3 inhibitors [31]. …”

Resveratrol and curcumin synergistically induces apoptosis in cigarette smoke condensate transformed breast epithelial cells through a p21Waf1/Cip1 mediated inhibition of Hh-Gli signaling

“…A significant decrease in extracellular level of vascular endothelial growth factor (VEGF) has been associated with apoptosis following Res treatment in breast cancer cells (Garvin et al, 2006). Recent studies also suggest that Res inhibits SHH signaling in human chronic and acute myeloid leukemic (CML and AML) cells indicating that Res could be used as a potent agent for the treatment of some aggressive cancer types (Liao et al, 2012;Su et al, 2014). However, Res metabolites have very short half-life and are prone to rapid renal clearance.…”